SEARCH OUR PAGES

Products

Products

Our pipeline
Delivering first-in-class immunotherapies
of activation and regulation

OSE Immunotherapeutics’ team has unique expertise and experience in immunological target discovery that serves as the basis for the development of innovative agonists and antagonists for application in immuno-oncology and autoimmune diseases.

OSE Immunotherapeutics has a balanced clinical and preclinical portfolio of products with a diversified risk profile.

OSE Immunotherapeutics’ R&D expertise in immunology has translated into several first-in-class products that activate or regulate the immune system and are being developed in a wide range of clinical indications. Its approach has been validated through partnerships with academic institutions and leading global pharmaceutical companies.

OSE Immunotherapeutics has a proven ability to deliver novel therapeutic products from target identification to clinical outcomes:

  •  Phase 3 asset (Tedopi®) with positive Step-1 results in non-small cell lung cancer post-checkpoint inhibitor therapy: Primary endpoint met: demonstrated 12-month overall survival rate in Tedopi® treated patients – Results at ESMO 2020
  • 4 clinical stage assets in immuno-oncology and auto-immunity
    And a second generation COVID-19 prophylactic vaccine program with positive results in preclinical and human ex vivo settings.
  • 3 areas of expertise within our immunology research platform: T-cell-based vaccination, immuno-oncology (focus on myeloid targets), and auto-immunity & inflammation.

Endorsed by significant partnerships with Servier and Boehringer Ingelheim for up to €1.3Bn in milestones (€60 M already received since 2016)

 

Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
Vaccines
Tedopi®
Neoepitopes
Advanced pancreatic cancer
Combo with PD1 Opdivo® ongoing
Tedopi®
Neoepitopes
NSCLC post ICI failure
Positive Step-1 results : Survival and safety
CoVepiT
Optimized Neoepitopes of SARS-CoV-2
COVID-19 vaccine
Positive preclinical results (August 2020)
Expected Q1 2021

Platform

  • Target Modality Neoepitopes
  • Indication Advanced pancreatic cancer
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 Combo with PD1 Opdivo® ongoing
  • Phase 3
  • Partners
  • Target Modality Neoepitopes
  • Indication NSCLC post ICI failure
  • Pre-Clinical POC
  • Phase 1
  • Phase 2
  • Phase 3 Positive Step-1 results : Survival and safety
  • Partners
  • Target Modality Optimized Neoepitopes of SARS-CoV-2
  • Indication COVID-19 vaccine
  • Pre-Clinical POC Positive preclinical results (August 2020)
  • Phase 1 Expected Q1 2021
  • Phase 2
  • Phase 3
  • Partners
Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
Immuno-Oncology
BI 765063 (OSE-172)
SIRPa/CD-47 Antagonist
Advanced solid tumours
Ongoing
CLEC-1
"Don't Eat Me" signal - Myeloid checkpoint
Various cancers
Ongoing
BiCKI®
T Cells + Innovative targets
Various cancers
Ongoing

Platform

  • Target Modality SIRPa/CD-47 Antagonist
  • Indication Advanced solid tumours
  • Pre-Clinical POC
  • Phase 1 Ongoing
  • Phase 2
  • Phase 3
  • Partners
  • Target Modality "Don't Eat Me" signal - Myeloid checkpoint
  • Indication Various cancers
  • Pre-Clinical POC Ongoing
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
  • Target Modality T Cells + Innovative targets
  • Indication Various cancers
  • Pre-Clinical POC Ongoing
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
Auto-Immunity & Inflammation
OSE-127
IL7-R Antagonist
UC; Sjögren
On-going in UC; planned in Sjögren
FR104
CD28 Antagonist
Auto-immune diseases & Transplantation
On-going Phase 1/2 in renal transplantation
OSE-230
Anti-ChemR23 Agonist
Resolution of inflammation
2020

Platform

  • Target Modality IL7-R Antagonist
  • Indication UC; Sjögren
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 On-going in UC; planned in Sjögren
  • Phase 3
  • Partners
  • Target Modality CD28 Antagonist
  • Indication Auto-immune diseases & Transplantation
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 On-going Phase 1/2 in renal transplantation
  • Phase 3
  • Partners
  • Target Modality Anti-ChemR23 Agonist
  • Indication Resolution of inflammation
  • Pre-Clinical POC 2020
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners